Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma. by Slebos, R. J. et al.
British Journal of Cancer (1996) 74, 165-171
© 1996 Stockton Press All rights reserved 0007-0920/96 $12.00
Clinical and pathological associations with p53 tumour-suppressor gene
mutations and expression ofp21WAF1/CiP1 in colorectal carcinoma
RJCSlebos', 10 Baas"2, MClement', MPolak', J-WMulder' 2, FM van denBerg', SR Hamilton2'3
and GJA Offerhaus" 2
'Department ofPathology, Academic Medical Centre, University ofAmsterdam, Meibergdreef9, 1105 AZ Amsterdam, The
Netherlands; 2Department ofPathology and 3Oncology Centre, The Johns Hopkins University School of Medicine, 632 Ross
Research Building, 720 Rutland Avenue, Baltimore, MD 21205, USA.
Summary Inactivation of the p53 tumour-suppressor gene is common in a wide variety of human neoplasms.
In the majority of cases, single point mutations in the protein-encoding sequence of p53 lead to positive
immunohistochemistry (IHC) for the p53 protein, and are accompanied by loss of the wild-type allele.
Recently, the WAFI/Cipi gene was identified as one of the genes induced by wild-type p53, and increased
expression of p2IWAFI/ciPl has been found to reflect the status of the p53 tumour-suppressor pathway. We
investigated the inactivation of p53 in a' relatively small, but well-characterised, group of 46 colorectal
carcinomas that were previously studied for allelic alterations, ras oncogene mutations and DNA aneuploidy.
Alterations in p53 were identified by IHC, loss of 17p and DNA sequence analysis of exons 5-8, whereas
p21WAFI/cipl protein expression was determined by IHC. p53 mutations were identified in 19 of the 46 tumours
(41%), whereas positive IHC for p53 was found in 21 of the 46 tumours (46%). Positive IHC for p2IWAFI/cipl
was detected in 16 of 42 cases (38%). We found no relationship between p2IWAF1/cipl staining and p53 protein
expression or p53 mutational status. Inactivating mutations in the p53 gene correlated with LOH at 17p but
not with LOH at 5q or 18q, Dukes' stage, tumour grade or DNA ploidy. There was a higher survival rate
independent of Dukes' stage in the group with no alterations in p53 compared with those with evidence of
dysfunction ofp53, but the difference was not statistically significant. We conclude that inactivation ofp53 and
altered expression ofp21WAFI/ciPl are common in colorectal carcinoma but do not correlate with each other or
with the clinical or pathological parameters investigated.
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Colorectal cancer is the second most prevalent cancer in the
Western world (Boring et al., 1991). Recent studies have
elucidated several genetic changes associated with this type of
cancer. Activating point mutations in ras oncogenes are
common in colorectal cancer and are typically found in more
than 50% of tumours, whereas loss of heterozygosity (LOH)
is frequently found at 5q (APC), 17p (p53), and 18q (DCC)
(Vogelstein et al., 1988). According to Knudson's model of
suppressor-gene function, such losses are thought to reveal
inactivating mutations in the target genes within such regions
(Knudson, 1971).
Alterations in the p53 tumour-suppressor gene are among
the most frequently encountered genetic aberrations in
human malignancies (Hollstein et al., 1991), which suggests
a central role for the p53 protein in human carcinogenesis.
The wild-type p53 protein suppresses tumour cell growth,
binds to specific DNA sequences and participates in cell-cycle
regulation (for review see Levine, 1992; Kern, 1994).
Inactivating mutations in the p53 tumour-suppressor gene
are very frequent in human colorectal carcinomas and are
usually accompanied by loss of the remaining wild-type copy
of the gene (Baker et al., 1989, 1990; Campo et al., 1991;
Cunningham et al., 1992). As early studies indicated that the
vast majority of p53 gene mutations are located in exons 5-
8, mutational analyses were principally confined to these
exons. In addition, not all sequence alterations that lead to
an amino acid change in the p53 protein result in impaired
p53 function. Examples include temperature-sensitive forms
of p53 (Halevy et al., 1990) and mutations that apparently
have limited activity in assays for p53 function (Frebourg et
al., 1992; Srivastava et al., 1993). For these reasons,
mutational analysis of the p53 gene will only reveal a subset
of tumours with p53 dysfunction.
A second method for the detection of p53 inactivation is
based on the fact that the majority of inactivating mutations
in p53 lead to an increased half-life of the p53 protein.
Although p53 protein levels in cells with wild-type p53 are
too low to detect by routine immunohistochemistry, most p53
gene mutations lead to the accumulation of p53 protein,
which is easily detectable with this technique (van den Berg et
al., 1989). Because of the relative ease of this approach, a
large number of studies have investigated alterations in p53
using immunohistochemistry (Campo et al., 1991; Cunning-
ham et al., 1992; Kaklamanis et al., 1993; Auvinen et al.,
1994; Scott et al., 1991; Starzynska et al., 1992; Bell et al.,
1993). In some reports these findings were accompanied by a
mutational a'nalysis of exons 5-8 of the p53 gene
(Cunningham et al., 1992; Cripps et al., 1994). However,
the comparison of the results obtained with these studies is
often difficult because of the use of different antibodies and
experimental conditions that greatly,influence the number of
p53-positive cells (Baas et al., 1994). It has also been reported
that not all inactivating point mutations in p53 lead to
protein accumulation detectable by IHC (Rodrigues et al.,
1990). In addition, mutations resulting in a truncated p53
protein, such as frame-shift or nonsense mutations, will not
yield detectable p53 protein and thus give a false-negative
result when only immunohistochemical detection methods are
used.
Recently, a gene that can be activated by wild-type p53
was described, WAFI/Cipi (El-Deiry et al., 1993; Harper et
al., 1993). The WAFI/Cipl gene product, p2lWAFI/cipl, is a
general inhibitor of cyclin-dependent kinases (CDKs), which
regulate entry into the DNA synthesis phase of the cell cycle.
Apart from induction by wild-type p53, activation of the
WAFI/Cipi gene can also occur through mechanisms
independent of p53 (Dulic et al., 1994; Zhang et al., 1994;
El-Deiry et al., 1995). As expression of the WAFI/Cip] gene
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is induced by wild-type p53 protein, the levels of p2lWAFI/Cipl
protein could potentially reflect the functional status of p53
in cancer cells.
Because of the shortcomings in each assay to test for
alterations in p53, we employed all three methods (LOH for
17p, p53 IHC and p53 sequence analysis) to investigate
possible alterations in the p53 tumour-suppressor pathway.
In addition, we investigated the expression of p2lWAF'/ciPl as
a potential marker for the status of p53, a relationship that
has not yet been studied in detail. The results from this
analysis were compared with alterations in other molecular
markers and with clinical and pathological data obtained in
previous studies on the same group of colorectal carcinomas.
Materials and methods
Tumour specimens
A group of 46 colorectal neoplasms collected by the Bowel
Tumour Working Group Bank at The Johns Hopkins
Hospital (Baltimore, MD, USA) was investigated. The
specimens were obtained by surgical resection for adenocar-
cinoma of the colon or rectum between 1983 and 1987.
Previous studies on these samples have been reported for
fractional allelic loss (FAL), ras point mutations, specific
allelic deletions of 5q, 17p and 18q (Kern et al., 1989), DNA
ploidy (Offerhaus et al., 1992), and nuclear morphometry
(Mulder et al., 1992). FAL was defined as the number of
chromosomal arms having allelic loss, divided by the total
number of informative chromosomal arms (Kern et al.,
1989). There were 24 men and 22 women in the study,
between 49 and 83 years of age at the time of surgery.
Routine histopathological classification was done on all
samples, while staging was according to Dukes (1932).
Molecular analysis of the p53 gene
Somatic mutations in the p53 gene were evaluated in all of
the 46 colorectal carcinomas. From routine formalin-fixed
paraffin-embedded specimens, areas rich in tumour cells were
carefully dissected and used for DNA isolation (Baker et al.,
1989; Vogelstein et al., 1988). Exons 5-8 were amplified
separately by polymerase chain reaction (PCR) using
primers and conditions as described elsewhere (DiGiuseppe
et al., 1994). Mutations in the p53 gene were identified by
analysing the PCR products by denaturing gradient gel
electrophoresis (DGGE) as described previously (DiGiuseppe
et al., 1994; Hamelin et al., 1993). Exons positive on DGGE
were amplified by PCR using p53-specific primers and
cloned into the plasmid vector pBluescript (Stratagene, La
Jolla, CA, USA). A minimum of 100 individual bacterial
clones were then pooled and used for DNA isolation.
Bidirectional DNA sequence analysis was performed using
Sequenase Version 2 (United States Biochemicals, Cleveland,
OH, USA) (Baker et al., 1990). PCR and sequencing
conditions have been described previously (Baas et al.,
1995; Kessis et al., 1993).
Immunohistochemistry for p53 and p21WAFI/cipl
Immunohistochemistry for p53 was performed in all 46
colorectal carcinomas with the antibody D07 (Dakopatts,
Glostrup, Denmark) as described previously (Baas et al.,
1994). p2lWAFI/CiPl protein was detected with antibody Ab-I
for WAFI (Oncogene Science, Cambridge, MA) using
citrate buffer for antigen enhancement (Baas et al., 1994),
with final detection through standard avidin-biotin staining
methods. Slides were scored independently by two observers
(GJAO and IOB) and categorised into two groups: no
expression (less than 10% positive tumour cells) and positive
expression (more than 10% staining tumour cells)
(Cunningham et al., 1992; Kaklamanis et al., 1993; Cripps
et al., 1994).
Statistical analysis
Differences in frequencies were evaluated by two-sided
Fisher's exact test or by x2 test for trend. P-values less than
0.05 were considered statistically significant. For a multi-
variate survival analysis, Kaplan-Meier curves were plotted
for p53 mutation only, p53 IHC and p21WAFl/ciPl IHC. In an
attempt to compensate for the shortcomings of the assays for
p53 status, tumours were also categorised into two groups
based upon the number of alteration as measured by the
three p53 assays (LOH at 17p, p53 IHC and p53 gene
mutation). When two or more of these assays showed
alterations in p53, inactivation of the p53 tumour suppressor
was considered to be present, whereas the remainder of the
tumours were considered to be wild type for p53. A
multivariate survival analysis based upon this classification
was performed for the total group of tumours, but also for
Dukes' B and C cases only, to minimise confounding by
stage. Statistical significance of the survival difference was
tested by log-rank.
Table I Somatic mutations in p53 in colorectal carcinoma specimens
Sample Exon Codon Base change Amino acid change p53 IHC' Number of17p alleles.
4 7 245 GGC-+GAC Gly--Asp 1 1
10 7 248 CGG-TGG Arg--Trp 1 1
12 6 189 GCC-+ACC Ala--Thr 1 1
15 7 248 CGG-+TGG Arg-Trp 1 1
16 5 172 GTT-TTT Val-+Phe 1 1
18 5 179 CAT-TAT His-+Tyr 1 1
22 7 248 CGG-+CAG Arg-*Gln 0 1
26 6 211 ACT-+GCT Thr-eAla 1 1
30 7 248 CGG-+CAG Arg-+Gln 1 1
34 6 198 GAA-.TAA Glu-+STOP 0 2
35 8 302 GGG-+G-G STOP at 344 0 1
36 6 196 CGA-TGA Arg-+STOP 0 1
40 6 216 GTG-.G-G STOP at 246 0 1
41 5 168 CAC-TAC His-Tyr 1 1
6 191 -192 CTC-- - - Pro-+Del
42 6 220 TAT-TGT Tyr-+Cys 0 1
53 8 286 GAA-+AAA Glu-+Lys 1 1
58 5 175 CGC-+CAC Arg-+His 0 1
61 6 196 CGA-+TGA Arg-+STOP 0 1
71 8 262 GGT-+GAT Gly- Asp 0 1
269 AGC--AAC Ser-+Asn
ap53 immunohistochemistry negative=0, p53 IHC positive= 1.Results
DNA sequence analysis of p53 revealed missense mutations
in 14 samples (30%), while five samples (11%) harboured
nonsense mutations or frame shifts resulting in premature
protein termination (Table I). In three of these five cases, a
simple base change resulted in termination codons (samples
34, 36, and 61), whereas samples 35 and 40 had a one-base
pair deletion that altered the open reading frame (Figure 1).
For sample number 35 the deletion was in codon 302, leading
to an aberrant protein terminating at codon 344, whereas in
sample number 40 the deletion was at codon 216, leading to a
stop at codon 246. Several samples showed stronger signals
for the mutated sequence than for the wild-type sequence on
the pooled DNAs, indicating loss of the wild-type allele in
these cases (samples 10 and 12). LOH at 17p on DNAs from
cryostat sections had been identified previously for these
samples (Kern et al., 1989).
Sample number 71 harboured two sequence alterations in
exon 8 (Table I). From this sample eight individual plasmid
clones were analysed to determine the origin of these two
mutations. One of the resulting clones had the wild-type exon
8, while the other seven contained both mutations, indicating
that both mutations were originally present in the same p53
allele. Sample number 41 also had multiple mutations: a
three-nucleotide deletion in exon 6 that deleted one of two
prolines, and two different mutations in exon 5, one in codon
168 (CAC-+TAC, histidine to tyrosine) and one in codon 174
that did not result in an amino acid change (AGG-+AGA,
arginine). Clonal analysis of seven individual plasmid clones
showed that the two exon 5 mutations occurred in different
DNA strands: the codon 168 mutation was found in one
clone, and the codon 174 mutation was found in three clones.
The remaining four clones were wild type. Two additional
samples harboured gene mutations that did not alter the
protein-encoding sequence. Sample number 6 was mutated at
codon 217 (GTG-)GTA, valine) and sample number 48 had
a mutation at codon 197 (GTG-+GTA, valine).
To further assess the p53 status of the colorectal
carcinomas, the samples were also analysed for p53 protein
accumulation using immunohistochemistry. In this analysis
21 samples showed positive nuclear staining for p53 (46%)
(Table II). When the presence of p53 gene mutations was
compared with positive immunohistochemical staining for the
p53 protein, a statistically significant correlation between
positive staining and missense mutations was found (Fisher's
exact test: P=0.027).
When the clinical and pathological parameters were
compared with p53 gene mutational status, only one
parameter, i.e. tumour size, showed a statistically significant
difference between the p53 wild-type and mutant group
(Table III). For the comparison of p53 mutations with
tumour size, four groups were distinguished: 0-4 cm, 4-
6 cm, 6-8 cm and over 8 cm. Mutations in p53 were more
Table II Comparison of p53 and p21WAF1/Cipl immunohistochem-
istry with p53 gene mutation in colorectal carcinomas
p53 gene mutation
Wild-type Missense Nonsense Total
p53 immunohistochemistrya
Negative 16 4 5 25
Positive 11 10 0 21
Total 27 14 5 46
p21WAFI/Cipl immunohistochemistry
Negative 12 11 3 26
Positive 12 2 2 16
Total 24 13 5 42
ap53 immunohistochemistry compared withp53 wild-type/nonsense
and p53 missense mutations: P=0.027 (Fisher's exact test).
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often found in smaller than in larger tumours (P= 0.044, X2
test for trend). No differences between the p53-negative and
-positive groups were found with respect to Dukes' stage, age
at diagnosis, gender or tumour localisation and differentia-
tion.
Mutations in the p53 gene also showed a significant
association with loss of the wild-type p53 allele on
chromosome 17p (Fisher's exact test: P=0.016), whereas no
correlation was found between p53 gene mutations and LOH
at 5q and 18q (Table IV). Activating point mutations in ras
a
Sample 4
T
A
C
G-A _p
G
C
G
C
T
C
C
T
G
G
G
Sample 3
A T C G A T C
exon 7
b
Sample 35 Sample 61
A C G T A C G T
exon 8 (reverse)
Figure 1 Detection of p53 point mutations by DNA sequence
analysis of selected DGGE-positive PCR products. (a) Example
of a point mutation in exon 7 at position 245 (sample 4), and the
same region for a sample with a wild-type exon 7 sequence. (b)
Example of a 1 bp deletion in sample 35 at position 302 leading to
a frame shift. The corresponding region of sample 61 indicated
the wild-type p53 sequence. The sequence shown was taken from
the antisense (reverse) strand.p53 and p21WAF1/CIPl in colorectal carcinoma
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oncogenes appeared to occur independently of p53 gene
mutations, and FAL did not correlate with p53 status (data
from Kern et al., 1989). We previously studied DNA ploidy
in this group of colorectal tumours (Offerhaus et al., 1992),
but when these data were compared with those obtained with
the p53 sequence analysis we did not find a correlation
between the two parameters.
Survival analysis for p53 gene mutation or p53 IHC did
not identify statistically significant differences between the
p53-positive and p53-negative groups (data not shown). To
compensate for possible shortcomings in these individual
assays, two additional groups were composed based upon all
alterations found in the p53 locus, in p53 protein expression
and by DNA sequence analysis. The 'p53-inactivated' group
was composed of 18 tumours with DNA sequence alterations
in p53 and allelic loss of 17p, along with eight tumours that
had no evidence of p53 sequence mutations but showed a
positive p53 IHC and LOH at 17p. Nineteen tumours that
lacked p53 sequence mutations and LOH at 17p, and one
case (number 34) that harboured a STOP codon but did not
show loss of 17p or positive p53 IHC, were classified as 'p53
wild-type'. The Kaplan-Meier curves for survival analysis
comparing the two groups are shown in Figure 2a. Although
there was a pattern for better survival in patients with an
intact p53 tumour-suppressor pathway (the 'p53 wild-type'
group), especially after adjustment for Dukes' stage, this did
not reach statistical significance (log-rank for the entire
group, P=0.3; and for Dukes' B and C cases, P=0.2). The
same trend towards a better prognosis in the p53-negative
group was found when only p53 gene mutations were
considered.
Forty-two of the 46 samples were available for p21WAFI'Cipl
immunohistochemistry, of which 16 (35%) showed positive
staining (Figure 3). In all cases positive staining for
p21WAFI/Cipi was localised to the nucleus, as was the case
for p53 staining. No association between p2lWAFI/Cipl protein
staining and p53 protein accumulation could be demon-
strated in this group of tumours. Thus, mutations in the p53
gene did not preclude increased levels of p21 WAFI/Cipl protein
expression. In this respect, the five cases with premature
termination codons in the p53 coding sequence are of special
interest. Two of these stained positively for p21WAFI/Cipl
whereas the other three stained negatively, suggesting p53-
independent routes of p21WAFI/Cipi induction. Expression of
p2WAFI/cipl did not show a significant correlation with any of
Table IV Comparison of p53 gene mutation and p21WAF/Cipl
immunohistochemistry with fractional alleic loss, DNA Ploidy, LOH
at 5q, 17p and 18q, and ras oncogene mutations in 46 colorectal
carcinomas
Genetic marker
Fractional allelic lossb
< 0.2
> 0.2
DNA ploidyc
Diploid
Aneuploid
ras oncogene muta-
tion
Wild-type
Mutated
LOH (no loss/loss)b
5q
17qe
18qf
p53 gene mutation
Wild-type Mutant
p21WAFJ CiPlIHCc
Negative Positive
15 9 10 12
12 10 16 4
8 3 4 5
19 16 22 1 1
14 5 11 7
13 14 15 9
17/10 12/7 16/10 11/5
10/17 1/18 2/24 7/9
8/19 4/13 5/20 6/9
aData available for 42 cases. bData from Kern et al. (1989). cData
from Offerhaus et al. (1992). dPoint mutations in codons 12,13 and 61
of the H-, K-, and N-ras oncogenes (Kern et al.,1989). ep53 gene
mutation: P= 0.016 (Fisher's exact test). fData available for 44 cases
(p53 mutation), and 40 cases (p2IWAFIlciPlIHC).
a
c 0.7
0
0
C;)0
cJ
(n0.2
12 24 36 48
Time (months)
60 72
Table III Comparison of p53 gene mutations and p21WAFIlCipl
immunohistochemistry with clinical and pathological parameters in
46 colorectal carcinomas
p53 gene mutation p21WAFJ Cipi IHC'
Parameter Wild-type Mutated Negative Positive
Age at diagnosis 69 68 69 68
(median)
Gender (male/female) 12/15 12/7 14/12 9/7
Sizeb (cm) 4 4 4 2
Less than 4 8 11 9 8
4-6 10 3 11 2
6-8 5 1 2 4
Over 8
Site (right/left) 12/15 10/9 11/15 10/6
Differentiation
Good 2 4 2 3
Moderate 22 13 20 12
Poor 3 2 4 1
Dukes' stage
A 1 4 4 0
B 10 4 8 5
C 6 5 5 6
D 10 6 9 5
aData available for 42 cases. bp53 gene mutation: P=0.044 (X2-test
for trend).
c 0.75
0
10 4-
CD 0.5
0.25
0
b
0 12 24 36 48 60 72
Time (months)
Figure2 Kaplan-Meier survival curve according to the classifi-
cation of tumours into p53 wild-type and p53-inactivated groups
upon assays for LOH at 17p, p53 IHC and p53 sequence
mutations of the total group of 46 cases (a) (-), p53 negative;
(- -), p53 positive. Survivaf analysis for 42 cases for which
p2IFl/CIpl IHC was determined (b) (-), WAF1 negative;
(- - -), WAF1 positive. Log-rank statistical analysis was not
significantly different for both analyses.p53 and p21wAF1/ciP1 in colorectal carcinoma
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Figure 3 Immunohistochemistry for p21WAFI/Cipl in colorectal
carcinoma and non-neoplastic colonic epithelium. (a) the non-
neoplastic colonic epithelium shows nuclear staining in the upper
crypts and surface where the terminally differentiating cells are
located, but epithelial cells in the proliferative zone are negative
(original magnification x 140); Panel B: The colonic carcinoma
shows nuclear staining of most neoplastic cells but stromal cells
are negative (original magnification x 90).
the clinical and pathological parameters (Table III). No
difference was observed between the p2lWAFI/Cipl IHC-
negative and IHC-positive groups when compared with
FAL, DNA ploidy and LOH at Sq, 17p, or 18q (Table
IV). There was also no difference in survival between the
p2lWAFI/CiPl_negative and -positive group, although the
p2lWAFI/CiPl_positive group appeared to have a slightly better
survival than the p2lWAFI/CiPl_negative group (Figure 2b).
Expression of p21WAFI/Cipl was also found in the crypt
epithelium of normal, non-neoplastic colorectal mucosa.
Typically, epithelial cells lining the lower two-thirds of the
crypts, where proliferation takes place, were negative for
p21WAFI/CipI immunohistochemical staining. Positivity for
p21WAFI/CiPl was a consistent finding in the upper one-third
of the crypts and the surface epithelium, outside the
progenitor zone but where terminally differentiating crypt
cells are found. Staining for p53 was always negative in non-
neoplastic crypt epithelium.
Discussion
In this study we investigated the clinical significance of the
p53/WAFl pathway in colorectal cancer. The study group
consisted of 46 carcinomas that were previously investigated
for loss of heterozygosity at 5q, 17p and 18q (Kern et al.,
1989), activating point mutations in ras oncogenes (Kern et
al., 1989) and DNA ploidy (Offerhaus et al., 1992). Because
of these previous studies, this study group provided a unique
opportunity to compare alterations in p53 with these
previously studied alterations and with the clinical and
pathological features in this well-documented group. To our
knowledge, this is the first study to compare the clinical
relevance of a combination of the three assays for p53
inactivation, in comparison with a spectrum of other genetic
alterations.
Abnormalities of the p53 gene can be assessed by DNA
sequence analysis, immunohistochemistry to test for p53
protein accumulation and by allelic loss at 17p. Although
each of these methods gives an indication of loss of p53
function, they all have limitations. DNA sequence analysis is
elaborate and sometimes difficult on archival tumour
samples. The mutations found in p53 span several exons,
and the presence of contaminating normal cells may dilute
the mutant signal. We have employed DGGE to screen for
PCR fragments with mutations, a method that reliably
identifies exons that are mutated (Hamelin et al., 1993;
DiGiuseppe et al., 1994). In our study group, 19 of the 46
colorectal carcinomas (41%) showed inactivating mutations
in the p53 gene. This frequency is lower than, but not
significantly different from, those reported in the literature
(Rodrigues et al., 1990; Lothe et al., 1992; Hamelin et al.,
1994). Mutational 'hotspots' for p53 have been defined in
previous studies. About one-third of all mutations in
colorectal cancer occur in codons 175, 248 or 273. In the
present study 5 out of the 19 p53 mutation-positive cases
(26%) were mutated in one of these three codons, whereas
mutations in other codons that are frequently altered in
human neoplasms (codons 179, 196, 220, 245) were also
found. The two mutations found in sample number 71
(codons 262 and 269) have not been reported previously.
Detailed analysis of these mutations revealed that they were
present in the same allele of p53. In contrast, two mutations
in case number 41 were present in different alleles. Multiple
mutations in one tumour sample have been reported
previously (Baker et al., 1990; Hamelin et al., 1994), but
their biological significance remains uncertain.
Although DNA sequence analysis of exons 5-8 will detect
the majority ofthe mutations, inactivating mutations in other
exons, promoter sequences or positions affecting mRNA
splicing may still be present. When such mutations lead to
accumulation of p53 protein, detecting by immunohistochem-
istry will yield more accurate results than DNA sequence
analysis. Several immunohistochemical studies have investi-
gated the inactivation of p53. In some of these studies, a
positive p53 IHC was associated with shortened survival
(Starzynska et al., 1992; Auvinen et al., 1994), although the
effect was weak or absent in others (Scott et al., 1991; Bell et
al., 1993). We have previously reported a similar study in
which we did not find an association between p53 IHC and
survival (Mulder et al., 1995). In all these studies, the
methods used to detect p53 protein were similar, although
different antibodies for p53 were employed. From our own
experience, the choice of antibody can greatly influence the
number of cases that show positive staining (Baas et al.,
1994), and the use ofantigen retrieval procedures may lead to
an overestimation of the number of p53-positive cases (Baas
et al., 1996). LOH at 17p is also associated with p53
mutations (Baker et al., 1990). In one study, p53 gene
mutations correlated with shortened survival, 17p allelic loss,
location of the tumour and 5q and 18q LOH (Hamelin et al.,
1994). Although our study group was limited, a strong
association between p53 and 17p LOH was also found, but
we did not find any of the other associations. When only p53
sequence mutations were considered, inactivation of p53
appeared to predict a poorer prognosis, although the
difference did not reach statistical significance. Of note, in
the Dukes' B and C tumours, where a prognostic marker may
prove most valuable in clinical management, the differences
were not statistically significant, but our study group was
small.
ap53 md p2
c in colori scna
w ...
9 RJC Slebos et i
170
One of the main downstream effector molecules of p53 is
p2IW"CI'P, a cyclin-dependent kinase inhibitor. Induction
of p21wAl' p is directly dependent on wild-type p53
protein accumulation, such as occurs after the induction
of sublethal DNA damage (El-Deiry et al., 1993). Thus,
activation of p21W"-l'cP may reflect p53 status of tumour
cells. However, when p53 status was compared with
p2IWIF' cipI protein expression no obvious association
between the two parameters was found. This finding is in
agreement with recently published data, showing that a
direct relationship between protein expression of p53 and
p2lW"I'l9 is only observed after sublethal DNA damage,
but not under normal conditions (El-Deiry et al., 1995;
DiGiuseppe et al., 1995). We observed no association of
p2lw"lCPJ IHC with any of the clinical and pathological
parameters, a finding that would limit the use of
p21W-FI sP' IHC as a specific tumour marker, or as a
marker for cancer survival. Recently, p53-independent, cell-
type specific pathways leading to the induction of
p2lW"l CiPl have been reported (Michiele et al., 1994;
Halevy et al., 1995). Increased levels of p2lWAF'Icapl may
not only lead to cell cycle arrest after p53 protein
accumulation but may also be linked with terminal
differentiation of specialised cells (Parker et al., 1995).
Indeed, the highest levels of p2lw"l'Pl were found in
terminally differentiated colonic crypt cells in non-neoplastic
mucosa (El-Deiry et al., 1995), as in our study. The
observed pattern of p2lw'AFcP expression compares well
with the mutually exclusive relationship between prolifera-
tion and differentiation typical in many different non-
neoplastic tissue types, including colonic epithelium.
This study indicates that high p2lWAF''ciP' protein levels
are not unique to tumour cells with intact p53 function. In
colorectal carcinomas with a mutated p53 gene, cells positive
for p21w"'IP' staining probably harbour a functioning
differentiation pathway activated through a p53-independent
mechanism. Specimens positive for p21w /'cl showed a
heterogeneous staining pattern for p2lwAJ"'iPI, but the
signia of this finding is unclear. The p53 mutational
status in colorectal carcinoma cells is not reflected by the
levels of p2lw"I'P protein. Our study thus demonstrates
that the induction of p21w"'IP' itself through p53-
independent mechanisms may occur in a significant fraction
of colorectal tumours.
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